Evaluation of flaxseed effects on non-alcoholic fatty liver disease (NAFLD) in rabbits submitted to a hypercholesterolemic diet

Functional Foods in Health and Disease

Volumn 4, Issue 10, 2014, Pages 442-450

  Saad, Caroline Tatim ^a   Précoma, Dalton Bertolim ^b   Merlini, Alexandre Bueno ^a   Ioshii, Sérgio Ossamu ^b   Champoski, Ana Flávia ^b  

^a STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Experimental study; Flaxseed; Functional food; Non alcoholic fatty liver disease

Indexed keywords

EID: 84938414586     PISSN: 23787007     EISSN: 21603855     Source Type: Journal    
DOI: 10.31989/ffhd.v4i10.153     Document Type: Article

References (21)

1. Basaranoglu M; Kayacetin S; Yilmaz N; Kayacetin E; Tarcin O; Sonsuz A. Understanding mechanisms of the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol. 2010; 16(18):2223-6.
2. Volzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol. 2012; 18(27):3492-501.
3. Cerovic I; Mladenovic D; Jesic R; Naumovic T; Brankovic M; Vucevic D et al. Alcoholic liver disease/not-alcoholic fatty liver disease index: distinguish alcoholic from non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013; 25(8):899-904.
4. Cauchy F; Fuks D; Zarzavadjian Le Bian A; Belghiti J; Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: the new scourges? World J Hepatol 2014; 6(5):306-14.
5. Toshikuni N; Tsutsumi M; Arisawa T. Clinical differences between alcoholic liver disease and non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20(26):8393-406.
6. Chalasani N; Younossi Z; Lavine JE; Diehl AM; Brunt EM; Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107(6):811-26.
7. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013; 167(4):1109-17.
8. Sourianarayanane A, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 59(1):69-87.
9. Beaton MD. Current treatment options for non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol. 2012; 26(6):353-7.
10. Elliott C; Frith J; Day CP; Jones DE; Newton JL. Functional impairment in alcoholic fatty liver disease and non-alcoholic fatty liver disease is significant and persists over 3 years of follow-up. Dig Dis Sci 2013; 58(8):2883-91.
11. Colak Y; Tuncer I; Senates E; Ozturk O; Doganay L; Yilmaz Y. Non-alcoholic fatty liver disease: a nutritional approach. Metab Syndr Relat Disord. 2012; 10(3):161-6.
12. Prasad K, Mantha SV, Munir AD. et al. Reduction of hypercholesterolemic atherosclerosis by CDC - flaxseed with very low alpha - lonolenic acid. Atherosclerosis 136:367-75, 1998.
13. Prasad K. Antihypertensive activity of secoisolariciresinol diglucoside isolated from flaxseed: role of guanylate cyclase. Int J Angiol 13:7-14, 2004.
14. Fukumitsu S, Aida K, Shimizu H, Toyoda K. Flaxseed lignan lowers blood cholesterol and decreases liver disease risk factors in moderately hipercholesterolemic men. Nut Res. 2010; 30(7):441-6.
15. Wu H, Pan A, Yu Z, Qi Q, Lu L, Zhang G et al. Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome. J Nutr. 2010; 140(11):1937-42.
16. Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr. 2008; 27(1):65-74.
17. Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. Meta-analysis of the effects of flaxseed interventions on bloods lipids. Am J Clin Nutr. 2009; 90(2):288-97.
18. Cherian G, Hayat Z. Long-term effects of feeding flaxseeds on hepatic lipid characteristics and histopathology of laying hens. Poult Sci. 2009; 88(12):2555-61.
19. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007
20. Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Précoma DB. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis. 2011; 216(1):97-102.
21. Prim CR, Baroncini LA, Précoma LB, Caron PH, Winter G, Poletti MO, Précoma DB. Effects of linseed consumption for a short period of time on lipid profile and atherosclerotic lesions in rabbits fed a hypercholesterolaemic diet. Br J Nutr. 2012; 107(5):660-4.